Apolipoprotein E gene polymorphism: Effects on plasma lipids and risk of type 2 diabetes and coronary artery disease

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Chaudhary, Rajesh ^a   Likidlilid, Atip ^a   Peerapatdit, Thavatchai ^a   Tresukosol, Damras ^a   Srisuma, Sorachai ^a   Ratanamaneechat, Suphachai ^a   Sriratanasathavorn, Charn ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Apolipoprotein E; Coronary artery disease; Hyperglycemia; Polymorphism; Restriction fragment length polymorphism; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; GENE FREQUENCY; GENOTYPE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; RISK; RISK ASSESSMENT; STATISTICAL MODEL; THAILAND;

APOLIPOPROTEINS E; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIPIDS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; THAILAND;

EID: 84859929415     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-36     Document Type: Article

References (58)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431. 10.2337/diacare.21.9.1414, 9727886.
2. Aekplakorn W, Stolk RP, Neal B, Suriyawongpaisal P, Chongsuvivatwong V, Cheepudomwit S, Woodward M. The prevalence and management of diabetes in Thai adults: the international collaborative study of cardiovascular disease in Asia. Diabetes Care 2003, 26:2758-2763. 10.2337/diacare.26.10.2758, 14514576.
3. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992, 258:468-471. 10.1126/science.1411543, 1411543.
4. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992, 71:343-353. 10.1016/0092-8674(92)90362-G, 1423598.
5. Li Y, Li X, Shi L, Yang M, Yang Y, Tao W, Xiong Y, Zhang Y, Yao Y. Association of adiponectin SNP + 45 and SNP + 276 with type 2 diabetes in Han Chinese populations: a meta-analysis of 26 case-control studies. PLoS One 2011, 6:e19686. 10.1371/journal.pone.0019686, 3092748, 21589658.
6. Zeljko HM, Skaric-Juric T, Narancic NS, Tomas Z, Baresic A, Salihovic MP, Starcevic B, Janicijevic B. E2 allele of the apolipoprotein E gene polymorphism is predictive for obesity status in Roma minority population of Croatia. Lipids Health Dis 2011, 10:9. 10.1186/1476-511X-10-9, 3025844, 21244662.
7. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752-1761. 535065, 15599400.
8. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002, 32(Suppl 3):14-23.
9. Martyn JA, Kaneki M, Yasuhara S. Obesity-induced insulin resistance and hyperglycemia: etiologic factors and molecular mechanisms. Anesthesiology 2008, 109:137-148. 10.1097/ALN.0b013e3181799d45, 18580184.
10. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002, 23:599-622. 10.1210/er.2001-0039, 12372842.
11. Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 2006, 5:295-309. 10.1038/nrd2005, 16582875.
12. Mahley RW, Rall SC. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000, 1:507-537. 10.1146/annurev.genom.1.1.507, 11701639.
13. Singh PP, Singh M, Mastana SS. APOE distribution in world populations with new data from India and the UK. Ann Hum Biol 2006, 33:279-308. 10.1080/03014460600594513, 17092867.
14. Siest G, Pillot T, Regis-Bailly A, Leininger-Muller B, Steinmetz J, Galteau MM, Visvikis S. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem 1995, 41:1068-1086.
15. Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, Sullivan PM, Maeda N. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest 1999, 103:1579-1586. 10.1172/JCI6172, 408371, 10359567.
16. Guang-da X, You-ying L, Zhi-song C, Yu-sheng H, Xiang-jiu Y. Apolipoprotein e4 allele is predictor of coronary artery disease death in elderly patients with type 2 diabetes mellitus. Atherosclerosis 2004, 175:77-81. 10.1016/j.atherosclerosis.2004.02.015, 15186949.
17. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 1996, 16:1250-1255. 10.1161/01.ATV.16.10.1250, 8857921.
18. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res 1992, 33:447-454.
19. Tatsanavivat P, Klungboonkrong V, Chirawatkul A, Bhuripanyo K, Manmontri A, Chitanondh H, Yipintsoi T. Prevalence of coronary heart disease and major cardiovascular risk factors in Thailand. Int J Epidemiol 1998, 27:405-409. 10.1093/ije/27.3.405, 9698127.
20. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053. 10.2337/diacare.27.5.1047, 15111519.
21. The Asia-Pacific Perspective: Redefining obesity and its treatment. 2000, 1-56. World Health Organization: WHO western pacific region.
22. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl 1):S62-S69. 2797383, 20042775, American Diabetes Association.
23. Richard P, Thomas G, de Zulueta MP, De Gennes JL, Thomas M, Cassaigne A, Bereziat G, Iron A. Common and rare genotypes of human apolipoprotein E determined by specific restriction profiles of polymerase chain reaction-amplified DNA. Clin Chem 1994, 40:24-29.
24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
25. Hermans MP, Sacks FM, Ahn SA, Rousseau MF. Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence. Cardiovasc Diabetol 2011, 10:20. 10.1186/1475-2840-10-20, 3056766, 21356116.
26. Krauss RM, Siri PW. Dyslipidemia in type 2 diabetes. Med Clin North Am 2004, 88:897-909. x, 10.1016/j.mcna.2004.04.004, 15308384.
27. Jenkins AJ, Rowley KG, Lyons TJ, Best JD, Hill MA, Klein RL. Lipoproteins and diabetic microvascular complications. Curr Pharm Des 2004, 10:3395-3418. 10.2174/1381612043383188, 15544524.
28. Bitzur R, Cohen H, Kamari Y, Shaish A, Harats D. Triglycerides and HDL cholesterol: stars or second leads in diabetes?. Diabetes Care 2009, 32(Suppl 2):S373-S377. 2811435, 19875584.
29. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010, 53:1270-1287. 10.1007/s00125-010-1684-1, 2877338, 20361178.
30. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009, 5:150-159. 10.1038/ncpendmet1066, 19229235.
31. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002, 155:487-495. 10.1093/aje/155.6.487, 11882522.
32. Eichner JE, Kuller LH, Orchard TJ, Grandits GA, McCallum LM, Ferrell RE, Neaton JD. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol 1993, 71:160-165. 10.1016/0002-9149(93)90732-R, 8421977.
33. van Bockxmeer FM, Mamotte CD. Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. Lancet 1992, 340:879-880. 10.1016/0140-6736(92)93288-X, 1357300.
34. Kuusi T, Nieminen MS, Ehnholm C, Yki-Jarvinen H, Valle M, Nikkila EA, Taskinen MR. Apoprotein E polymorphism and coronary artery disease. Increased prevalence of apolipoprotein E-4 in angiographically verified coronary patients. Arteriosclerosis 1989, 9:237-241. 10.1161/01.ATV.9.2.237, 2923580.
35. Corbo RM, Vilardo T, Ruggeri M, Gemma AT, Scacchi R. Apolipoprotein E genotype and plasma levels in coronary artery disease. A case-control study in the Italian population. Clin Biochem 1999, 32:217-222. 10.1016/S0009-9120(99)00011-9, 10383084.
36. Attila G, Acarturk E, Eskandari G, Akpinar O, Tuli A, Kanadas IM, Kayrin L. Effects of apolipoprotein E genotypes and other risk factors on the development of coronary artery disease in Southern Turkey. Clinica chimica acta; international journal of clinical chemistry 2001, 312:191-196. 10.1016/S0009-8981(01)00624-6, 22452379.
37. Kumar P, Luthra K, Dwivedi M, Behl VK, Pandey RM, Misra A. Apolipoprotein E gene polymorphisms in patients with premature myocardial infarction: a case-controlled study in Asian Indians in North India. Ann Clin Biochem 2003, 40:382-387. 10.1258/000456303766477020, 12880539.
38. Yan S, Zhou X, Lin Q, Song Y. Association of polymorphism of apolipoprotein E gene with coronary heart disease in Han Chinese. Chin Med J (Engl) 1999, 112:224-227.
39. Anuurad E, Yamasaki M, Shachter N, Pearson TA, Berglund L. ApoE and ApoC-I polymorphisms: association of genotype with cardiovascular disease phenotype in African Americans. J Lipid Res 2009, 50:1472-1478. 10.1194/jlr.P900012-JLR200, 2694345, 19252179.
40. Stengard JH, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Genotypes with the apolipoprotein epsilon4 allele are predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men. Hum Genet 1996, 97:677-684. 10.1007/BF02281882, 8655152.
41. Kataoka S, Robbins DC, Cowan LD, Go O, Yeh JL, Devereux RB, Fabsitz RR, Lee ET, Welty TK, Howard BV. Apolipoprotein E polymorphism in American Indians and its relation to plasma lipoproteins and diabetes. The Strong Heart Study. Arterioscler Thromb Vasc Biol 1996, 16:918-925. 10.1161/01.ATV.16.8.918, 8696954.
42. McGill HC, McMahan CA. Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Am J Cardiol 1998, 82:30T-36T.
43. Murakami K, Okubo H, Sasaki S. Effect of dietary factors on incidence of type 2 diabetes: a systematic review of cohort studies. J Nutr Sci Vitaminol 2005, 51:292-310. 10.3177/jnsv.51.292, 16262005.
44. Bernstein MS, Costanza MC, James RW, Morris MA, Cambien F, Raoux S, Morabia A. Physical activity may modulate effects of ApoE genotype on lipid profile. Arterioscler Thromb Vasc Biol 2002, 22:133-140. 10.1161/hq0102.101819, 11788473.
45. Li J, Wang Q, Chai W, Chen MH, Liu Z, Shi W. Hyperglycemia in apolipoprotein E-deficient mouse strains with different atherosclerosis susceptibility. Cardiovasc Diabetol 2011, 10:117. 10.1186/1475-2840-10-117, 3273441, 22204493.
46. Tosukhowong P, Sangwatanaroj S, Jatuporn S, Prapunwattana P, Saengsiri A, Rattanapruks S, Srimahachota S, Udayachalerm W, Tangkijvanich P. The correlation between markers of oxidative stress and risk factors of coronary artery disease in Thai patients. Clin Hemorheol Microcirc 2003, 29:321-329.
47. Tan CE, Tai ES, Tan CS, Chia KS, Lee J, Chew SK, Ordovas JM. APOE polymorphism and lipid profile in three ethnic groups in the Singapore population. Atherosclerosis 2003, 170:253-260. 10.1016/S0021-9150(03)00232-6, 14612205.
48. Inamdar PA, Kelkar SM, Devasagayam TP, Bapat MM. Apolipoprotein E polymorphism in non-insulin-dependent diabetics of Mumbai, India and its effect on plasma lipids and lipoproteins. Diabetes Res Clin Pract 2000, 47:217-223. 10.1016/S0168-8227(99)00126-6, 10741571.
49. Fernandez ML, Webb D. The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk. J Am Coll Nutr 2008, 27:1-5.
50. Washio M, Sasazuki S, Kodama H, Yoshimasu PK, Liu Y, Tanaka K, Tokunaga S, Kono PS, Arai H, Koyanagi S, Hiyamuta K, Doi Y, Kawano MT, Nakagaki MO, Takada K, Nii MT, Shirai K, Ideishi MM, Arakawa MK, Mohri MM, Takeshita A. Role of hypertension, dyslipidemia and diabetes mellitus in the development of coronary atherosclerosis in Japan. Jpn Circ J 2001, 65:731-737. 10.1253/jcj.65.731, 11502050.
51. Frikke-Schmidt R. Context-dependent and invariant associations between APOE genotype and levels of lipoproteins and risk of ischemic heart disease: a review. Scand J Clin Lab Invest Suppl 2000, 233:3-25.
52. Singh PP, Singh M, Bhatnagar DP, Kaur TP, Gaur SK. Apolipoprotein E polymorphism and its relation to plasma lipids in coronary heart disease. Indian J Med Sci 2008, 62:105-112. 10.4103/0019-5359.39613, 18376083.
53. Chaaba R, Attia N, Hammami S, Smaoui M, Ben Hamda K, Mahjoub S, Hammami M. Association between apolipoprotein E polymorphism, lipids, and coronary artery disease in Tunisian type 2 diabetes. J Clin Lipidol 2008, 2:360-364. 10.1016/j.jacl.2008.08.441, 21291761.
54. Gomez-Coronado D, Alvarez JJ, Entrala A, Olmos JM, Herrera E, Lasuncion MA. Apolipoprotein E polymorphism in men and women from a Spanish population: allele frequencies and influence on plasma lipids and apolipoproteins. Atherosclerosis 1999, 147:167-176. 10.1016/S0021-9150(99)00168-9, 10525138.
55. Kolovou GD, Anagnostopoulou KK. Apolipoprotein E polymorphism, age and coronary heart disease. Ageing Res Rev 2007, 6:94-108. 10.1016/j.arr.2006.11.001, 17224309.
56. Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, Bales CW, Henes S, Samsa GP, Otvos JD, Kulkarni KR, Slentz CA. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002, 347:1483-1492. 10.1056/NEJMoa020194, 12421890.
57. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004, 109:2197-2202. 10.1161/01.CIR.0000126824.12785.B6, 15123532.
58. Gage J, Hasu M, Thabet M, Whitman SC. Caspase-1 Deficiency Decreases Atherosclerosis in Apolipoprotein E-Null Mice. Can J Cardiol 2012, 28:222-229.